FB 825

Drug Profile

FB 825

Alternative Names: Anti-CEmX monoclonal antibody - Fountain Biopharma; FB-825; h4B12

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Academia Sinica
  • Developer Fountain BioPharma
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; IgE receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Job syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Phase I Allergic asthma; Allergic rhinitis

Most Recent Events

  • 26 Oct 2017 Phase-II clinical trials in Atopic dermatitis in USA (IV) before October 2017 (9227300; MicroBioGroup and Fountain Biopharma pipeline, October 2017)
  • 11 Oct 2017 FB 825 receives Orphan Drug status for Job syndrome (Hyperimmunoglobulin E syndrome) in USA
  • 01 Feb 2016 Fountain BioPharma completes a phase I trial in Atopic dermatitis, allergic asthma and allergic rhinitis (In volunteers) in USA (NCT02309762)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top